BioMarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted Revenue per Share: MXN219.89 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN1,110.82
GF Value MXN1,407.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted Revenue per Share?

BioMarin Pharmaceutical MEX:BMRN 80 Cyclically Adjusted Revenue per Share is MXN219.89 as of Jun. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,407.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted revenue per share for the three months ended in Jun. 2026 was MXN88.804. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN219.89 for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioMarin Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioMarin Pharmaceutical was 34.80% per year. The lowest was 11.00% per year. And the median was 14.20% per year.

As of today (2026-09-05), BioMarin Pharmaceutical's current stock price is MXN1110.82. BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN219.89. BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is 5.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioMarin Pharmaceutical was 24.72. The lowest was 4.07. And the median was 11.14.


BioMarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1110.82/219.89
=5.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioMarin Pharmaceutical was 24.72. The lowest was 4.07. And the median was 11.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioMarin Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted Revenue per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.39 185.64 143.32 287.60 202.99

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.94 221.46 202.99 221.59 219.89

MEX:BMRN vs MDGL, CORT, ARWR: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=88.804/333.9520*333.9520
=88.804

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 32.269 241.428 44.636
201612 35.923 241.432 49.689
201703 33.115 243.801 45.360
201706 32.907 244.955 44.863
201709 34.632 246.819 46.858
201712 40.098 246.524 54.318
201803 38.516 249.554 51.542
201806 41.421 251.989 54.894
201809 41.283 252.439 54.613
201812 38.799 251.233 51.574
201903 43.606 254.202 57.286
201906 41.601 256.143 54.238
201909 48.961 256.759 63.681
201912 47.738 256.974 62.038
202003 62.897 258.115 81.377
202006 54.852 257.797 71.056
202009 53.283 260.280 68.365
202012 49.460 260.474 63.412
202103 53.887 264.877 67.940
202106 53.858 271.696 66.199
202109 45.873 274.310 55.847
202112 50.269 278.802 60.213
202203 53.062 287.504 61.634
202206 57.290 296.311 64.568
202209 54.769 296.808 61.623
202212 56.332 296.797 63.384
202303 55.311 301.836 61.196
202306 52.336 305.109 57.284
202309 52.968 307.789 57.470
202312 58.195 306.746 63.356
202403 54.040 312.332 57.781
202406 65.058 314.175 69.153
202409 74.482 315.301 78.888
202412 79.203 315.605 83.807
202503 77.590 319.799 81.024
202506 78.856 322.561 81.641
202509 74.141 324.800 76.230
202512 79.172 324.054 81.590
202603 69.898 330.213 70.689
202606 88.804 333.952 88.804

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN219.89 mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Cyclically Adjusted Revenue per Share of MXN219.89 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted Revenue per Share is MXN219.89. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share compare to MDGL and CORT?
BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share of MXN219.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted Revenue per Share is MXN219.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,407.52, compared to a current price of MXN1,110.82 — trading 21.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN219.89. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Cyclically Adjusted Revenue per Share is MXN219.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,110.82 is trading 21.1% below its estimated GF Value™ of MXN1,407.52. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for MEX:BMRN:

  • Cyclically Adjusted Revenue per Share: MXN219.89
  • GF Value™: MXN1,407.52 vs. price of MXN1,110.82 (21.1% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,110.82
Price
MXN1,407.52
GF Value